We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X19 Sep 22
According to the firm, Skysona is the only FDA-approved treatment to decrease the course of neurologic deterioration in…
16 Sep 22
The enlarged RIGImmune with the addition of Subintro will focus on advancing the development of novel RNA therapies…
14 Sep 22
Efzofitimod is an immunomodulator that is said to preferentially modify neuropilin-2 for suppressing innate and adaptive immune responses…
13 Sep 22
The collaboration will combine Microsoft’s computational services, cloud and AI technologies with Novo Nordisk’s drug discovery, development and…
13 Sep 22
The funding will be used to support the company's primary activities focused on real-world evidence production, healthcare data…
12 Sep 22
The approval was based on the results from a Phase 2/3 randomised, controlled trial on 4,526 kids aged…
12 Sep 22
Approval of Sotyktu was driven by the findings of the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical…
08 Sep 22
The market for plant-based supplements worldwide is currently at $7.3 billion and is expected to surge past $11.5 billion by 2028…
07 Sep 22
The European regulator found that the acquisition would provide Illumina with the ability and incentive to prevent GRAIL’s…